Mediastinal Lymph Node Sampling Following Positron Emission Tomography With Fluorodeoxyglucose Imaging in Lung Cancer Staging

Gupta, Naresh; Tamim, Wael J.; Graeber, Geoffrey; Bishop, Harry A.; Hobbs, Gerald R.

doi:10.1378/chest.120.2.521

Cited by 159 publications

(96 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4][5][6][7][8] Some of them evaluated histological findings of metastatic lymph nodes in detail, and they investigated causative factors for false-negative PET scans. However, to our knowledge, few studies have investigated the association between PET false-negative, unexpectedly proven lymph node metastasis and the histological features of primary tumors.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Haruki

Wakahara

Matsuoka

et al. 2017

ATCS

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Haruki

Wakahara

Matsuoka

et al. 2017

ATCS

View full text Add to dashboard Cite

“…In general, malignant tumors show higher FDG uptake than benign lesions due to overexpression of glucose membrane-transporters and glycolysispathway-control hexokinase in cancer cells [1]. However, false-positive and false-negative results of PET examination may still occur [2][3][4]. A tumor focus smaller than 4-5 mm in diameter may escape detection by current PET scanners.…”

Section: Introductionmentioning

confidence: 99%

Experience of Dual Time Point Brain F-18 FDG PET/CT Imaging in Patients with Infectious Disease

Kim

Park

et al. 2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Dual time point FDG PET imaging (DTPI) has been considered helpful for discrimination of benign and malignant disease, and staging lymph node status in patients with pulmonary malignancy. However, DTPI for benign disease has been rarely reported, and it may show a better description of metabolic status and extent of benign infectious disease than early imaging only. The authors report on the use F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging with additional delayed imaging on a 52-year-old man with sparganosis and a 70-year-old man with tuberculous meningitis. To the best of our knowledge, this is the first report on dual time point PET/CT imaging in patients with cerebral sparganosis and tuberculous meningitis.

show abstract

“…CT is the most commonly used imaging modality in radiotherapy and provides anatomic and morphologic information; however, compared with 18 F-FDG PET, CT lacks sensitivity and specificity in lung cancer patients for detecting disease (1). PET takes advantage of the increase in the glucose uptake within lesions and can provide metabolic and physiologic information about these lesions (2).…”

mentioning

confidence: 99%

Phased Versus Midventilation Attenuation-Corrected Respiration-Correlated PET for Patients with Non-Small Cell Lung Cancer

Rosario

Öllers²,

Bosmans³

et al. 2009

Journal of Nuclear Medicine Technology

View full text Add to dashboard Cite

Respiration-correlated PET (RCPET) can reduce motion artifacts, but image quality generally decreases. The use of phase-by-phase attenuation correction (PAC) for RCPET using respiration-correlated CT (RCCT) requires large computational resources, and tumor positions will not always match correctly because of different binning methods for CT and PET. In this study, we investigated whether PAC for RCPET can be replaced by midventilation attenuation correction (MidV-AC) for a group of lung cancer patients. Methods: RCPET/CT scans of 19 nonsmall cell lung cancer patients were performed. List-mode PET and CT data were binned and reconstructed into 8 phases. Two AC methods for RCPET were applied. First, the corresponding 8 RCCT phases were used for PAC. Then MidV-AC was used. Analyses were performed in terms of standardized uptake values (SUVs), volume recovery, contrast, and signal-to-noise ratio (SNR). Results: Average differences between PAC and MidV-AC for mean and maximum SUV were 1.0% and 0.9% (P 5 0.007 and P 5 0.002), respectively, whereas SNR, contrast, and volume did not differ significantly (P $ 0.2). Large motion amplitudes and irregular breathing revealed larger differences between phase 1 and MidV-AC values. Conclusion: Differences in SUV, volume, SNR, and contrast between PAC as available in currently used clinical software and MidV-AC for RCPET are small. MidV-AC provides an excellent surrogate for PAC for most lung cancer patients encountered in clinical practice.

show abstract

Mediastinal Lymph Node Sampling Following Positron Emission Tomography With Fluorodeoxyglucose Imaging in Lung Cancer Staging

Cited by 159 publications

References 17 publications

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Clinicopathological Characteristics of Lung Adenocarcinoma with Unexpected Lymph Node Metastasis

Experience of Dual Time Point Brain F-18 FDG PET/CT Imaging in Patients with Infectious Disease

Phased Versus Midventilation Attenuation-Corrected Respiration-Correlated PET for Patients with Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About